Active, not recruitingPhase 1NCT04750954
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
Studying Gastroenteropancreatic neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lowell B Anthony, M.DOhio State University Comprehensive Cancer Center LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 29 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (5)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04750954 on ClinicalTrials.govOther trials for Gastroenteropancreatic neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06356467Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENsIRCCS San Raffaele
- ACTIVE NOT RECRUITINGPHASE1NCT05262556NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasAmr Mohamed MD
- ACTIVE NOT RECRUITINGNANCT03012789Surgical Intervention and the NETestWren Laboratories LLC
See all trials for Gastroenteropancreatic neuroendocrine neoplasm →